Search clinical trials for: BMS-830216

Total 3144 results

Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Neoplasms

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

Australia
Bristol-Myers Squibb

Terminated

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

Psoriasis, Moderate to Severe

United States
San Antonio Cancer Institute

Completed

BMS-184476 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Persistent Disease

United States
Bristol-Myers Squibb

Withdrawn

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Healthy
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
The University of Hong Kong
Caritas Medical Centre, Hong Kong

Not yet recruiting

A Brief Body-mind-spirit Intervention to Promote Positive Emotions

Stress | Emotions
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants

Healthy Adult Volunteers
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

Healthy Volunteer

United States
Yale University
National Institute on Aging (NIA)

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Alzheimer Disease

United States
Matthew Dallos
Bristol-Myers Squibb

Terminated

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Solid Tumor | Sars-CoV2 | Hematological Malignancy

United States
Bristol-Myers Squibb

Completed

Phase 1 Study of Mesothelin-ADC

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Cardiac Failure | Myocardial Failure

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Renal Failure | Congestive Heart Failure | Kidney Failure | Cardiac Failure | Myocardial Failure

Poland, Czechia
Bristol-Myers Squibb

Completed

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Thrombosis

United Kingdom
Bristol-Myers Squibb

Terminated

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Healthy

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

Thrombosis | Renal Impairment | Factor XI | ESRD (End-Stage Renal Disease)

United States
Bristol-Myers Squibb

Completed

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Hepatic Insufficiency

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

BMS-599626 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

Healthy | Alzheimer's Disease

United States
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Spain, United States, Belgium, France, Italy, Netherlands, United Kingdom
Bristol-Myers Squibb

Terminated

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Tumors

United States, Belgium
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment

Unspecified Adult Solid Tumor, Protocol Specific
Bristol-Myers Squibb

Completed

Absolute Bioavailability of BMS-791325

Hepatitis C Virus Infection

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Advanced Cancer

United States, Israel, Australia, Austria, Canada, Italy
Tolerion, Inc.

Withdrawn

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN) (DAWN)

Diabetes Mellitus, Type 1

United States
Tolerion, Inc.

Withdrawn

Diabetes AutoimmunitY Withdrawn in Established Patients (DAY) (DAY)

Diabetes Mellitus, Type 1
Imperial College Healthcare NHS Trust
Imperial College London; University of Oxford; Oxford University Hospitals NHS...

Withdrawn

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations (SABRE)

Lymphoma | Leukemia | Immune Thrombocytopenia | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | Myeloma | Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Healthy Male Participants

United States
Allyx Therapeutics
Michael J. Fox Foundation for Parkinson's Research

Active, not recruiting

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

Dementia | Alzheimer Disease

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Completed

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Thrombosis

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers

Advanced Solid Tumors

Australia, Singapore
Bristol-Myers Squibb

Terminated

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Breast Cancer

United States
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France
Bristol-Myers Squibb

Completed

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States

Search clinical trials for: BMS-830216

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations